GLP-1 medications safe for GI patients in remission

Dr. Octavia Pickett-Blakely, a gastroenterologist in Philadelphia, spoke about the use of anti-obesity medications in patients with gastrointestinal (GI) conditions. She focused on the safety of these medications, especially GLP-1 receptor agonists like semaglutide and liraglutide. Many patients with GI issues, such as Crohn's disease, may struggle with weight gain due to steroid treatments used to manage their condition. Dr. Pickett-Blakely noted that using GLP-1 receptor agonists can be safe for patients with inflammatory bowel disease, as long as their condition is in remission. She emphasized the importance of consulting with a gastroenterologist to assess a patient’s health before starting these medications. However, for patients with conditions like gastroparesis, which slows down gastric emptying, GLP-1 receptor agonists might not be the best choice. In such cases, other medications like phentermine/topiramate or naltrexone/bupropion may be more suitable. It is crucial for doctors to understand the specific GI conditions of their patients and weigh the potential side effects of anti-obesity medications when deciding on treatment. As always, Dr. Pickett-Blakely encourages patients to consult their gastroenterologist for personalized advice.